carmustine
Commercial- Indications
- Brain cancer
Company intelligence / Profile preview
Guilford Pharmaceuticals successfully commercialized the GLIADEL® Wafer for brain tumors and AGGRASTAT® Injection for acute coronary syndrome. The company also advanced several novel product candidates into clinical development, including Aquavan Injection in Phase 2 trials for conscious sedation and GPI 1485 in Phase 2 trials for Parkinson's disease. Additional pipeline assets targeted neurological disorders, cancer, and other serious conditions.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Guilford Pharmaceuticals.